We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Contract Manufacturer’s Deficiency Prompts FDA Action Letter to Salix
Contract Manufacturer’s Deficiency Prompts FDA Action Letter to Salix
April 30, 2010
The FDA has issued an action letter to Salix Pharmaceuticals for its adult ulcerative colitis treatment Giazo, citing a deficiency in the contract manufacturing
facility referenced in Salix’s NDA.